Additional file 1 of Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction
Creators: name: Zheng, Rui
name: Zhang, Ke
name: Tan, Shanyue
name: Gao, Fang
name: Zhang, Yajie
name: Xu, Wenxia
name: Wang, Huabin
name: Gu, Dongying
name: Zhu, Lingjun
name: Li, Shuwei
name: Chu, Haiyan
name: Zhang, Zhengdong
name: Liu, Lingxiang
name: Du, Mulong
name: Wang, Meilin
Publisher: name: figshare
Year: 2022
Subjects: subject: Biophysics
subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Biotechnology
subject: Biological Sciences not elsewhere classified
subject: Information Systems not elsewhere classified
subject: Cancer

description: Additional file 1: Supplementary Materials and Methods. Table S1. Demographic and clinical characteristics of the subjects who participated in RNA-Seq and proteogenomic analysis. Table S2. Five differentially expressed circRNAs and significant fold changes. Table S3. Demographic and clinical characteristics of the subjects in FISH analysis. Table S4. Demographic and clinical characteristics of subjects with colorectal cancer and cancer-free controls. Table S5. Characteristics of patients with other types of cancer. Table S6. Demographic and clinical characteristics of the colorectal cancer patients before and after operation. Table S7. Characterization of circLPAR1-binding proteins. Table S8. The correlation between protein and its parental gene expression and prediction of RNA binding ability. Table S9. Sequences of circLPAR1 used for FISH analysis in the study. Table S10. Sequences of primers used for RT-qPCR in the study. Figure S1. The expression of circRNAs detected by RT-qPCR. Figure S2. The expression of circLPAR1 in CRC cells treated with actinomycin D and colorectal tumors. Figure S3. Characterization of exosomes derived from human plasma. Figure S4. The expression of traditional clinical biomarkers in plasma. Figure S5. ROC curve analysis of exosomal circLPAR1 and traditional clinical biomarkers in human plasma. Figure S6. Fluorescence observation of colorectal cancer cells after incubation with PKH67-labelled exosomes or non-exosomes. Figure S7. Fluorescence observation of colorectal cancer cells incubation with PKH67-labelled exosomes pretreated with cytochalasin D. Figure S8. The expression of circLPAR1 in exosomes derived from colorectal cancer cells. Figure S9. The effect of exosomal circLPAR1 on invasion and migration abilities of HCT116 cells. Figure S10. The effect of circLPAR1 overexpression on colorectal cancer cellular phenotypes. Figure S11. The cellular localization of circLPAR1 in colorectal cancer cells. Figure S12. MS2-CP-Flag was pulled down by anti-flag and evaluated by Western blot. Figure S13. The proteomic analysis showing 23 proteins levels based on 25 paired colorectal cancer tissues. Figure S14. Mass spectrometry analysis identification of eIF3h. Figure S15. The effect of BRD4 regulation by circLPAR1 on colorectal cancer cellular phenotype. Figure S16. The enrichment of miR-762 in the complex with MS2-CP-Flag. Figure S17. Effect of exosomal circLPAR1 on colorectal cancer progression in vivo.